Advertisement
Advertisement
AMGN
Amgen Inc
466.01
USDSponsored
+5.28
+1.15%
Oct 30, 15:59 UTC -4
Closed
After-Market
466.00
-0.01
0.00%
Amgen Inc (AMGN) Earnings
AMGN Earnings Reports
Positive Surprise Ratio
AMGN beat 38 of 42 last estimates.
90%
Next Report
Next Week
Date of Next Report
Nov 03, 2026
Estimate for Q3 26 (Revenue/ EPS)
$10.27B
/$5.90
Implied change from Q2 26 (Revenue/ EPS)
+2.17%
/-6.20%
Implied change from Q3 25 (Revenue/ EPS)
+7.48%
/+4.61%
Amgen Inc earnings per share and revenue
On Aug 04, 2026, AMGN reported earnings of 6.29 USD per share (EPS) for Q2 26, beating the estimate of 5.72 USD, resulting in a 9.81% surprise. Revenue reached 10.05 billion, compared to an expected 9.61 billion, with a 4.63% difference. The market reacted with a +4.57% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 13 analysts forecast an EPS of 5.90 USD, with revenue projected to reach 10.27 billion USD, implying an decrease of -6.20% EPS, and increase of 2.17% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AstraZeneca PLC
Report Date
Oct 30, 2026 For Q3 26
Estimate
$2.66
Actual
$2.79
Surprise
+4.56%
Regeneron Pharmaceuticals Inc
Report Date
Oct 30, 2026 For Q3 26
Estimate
$16.47
Actual
$20.07
Surprise
+21.79%
Insmed, Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$0.38
Actual
-$0.46
Surprise
-19.82%
Incyte Genomics Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$3.92
Actual
-$3.60
Surprise
+8.33%
Alnylam Pharmaceuticals, Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.65
Actual
$16.26
Surprise
+885.34%
Exelixis Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
$0.81
Actual
$0.94
Surprise
+15.64%
Ligand Pharmaceuticals Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$2.42
Actual
$2.67
Surprise
+9.91%
PTC Therapeutics, Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$0.34
Actual
$0.61
Surprise
+75.59%
Fortrea Holdings Inc. Common Stock
Report Date
Oct 29, 2026 For Q3 26
Estimate
$0.22
Actual
$0.28
Surprise
+26.53%
NovoCure Limited Ordinary Shares
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.09
Surprise
+63.88%
FAQ
What were Amgen Inc's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Amgen Inc reported EPS of $6.29, beating estimates by 9.81%, and revenue of $10.05B, 4.63% above expectations.
How did the market react to Amgen Inc's Q2 2026 earnings?
The stock price moved up 4.57%, changed from $390.02 before the earnings release to $407.83 the day after.
When is Amgen Inc expected to report next?
The next earning report is scheduled for Nov 03, 2026.
What are the forecasts for Amgen Inc's next earnings report?
Based on 13
analysts, Amgen Inc is expected to report EPS of $5.90 and revenue of $10.27B for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.